Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) faces a potential downside of -31.72%, indicating a lack of confidence among analysts.
Virios Therapeutics, Inc. (VIRI) shows a potential upside of 13.97%, making it the peer with the highest growth potential in the biotechnology sector.
Virax Biolabs Group Limited (VRAX) and Unicycive Therapeutics, Inc. (UNCY) present significant downside and moderate growth potential, respectively, highlighting the varied investment outlooks within the sector.
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is a biotechnology company focused on developing regenerative medicine products. CELZ is currently trading at $3.577, but with a target price of $2.44, analysts predict a potential downside of -31.72%. This negative outlook has led to CELZ being excluded from coverage, indicating a lack of confidence in its near-term performance.
In comparison, Virios Therapeutics, Inc. (VIRI) is trading at $0.155 with a target price of $0.1767, suggesting a potential upside of 13.97%. This positions VIRI as the peer with the highest growth potential among its biotechnology sector peers. The positive outlook for VIRI may attract investors looking for growth opportunities.
Virax Biolabs Group Limited (VRAX) is another peer in the biotechnology sector, currently priced at $1.71 with a target price of $0.9468. This indicates a potential downside of -44.63%, which is even more significant than CELZ’s. Such a large potential drop may deter investors from considering VRAX as a viable investment option.
Unicycive Therapeutics, Inc. (UNCY) is trading at $0.3665 with a target price of $0.3925, offering a potential upside of 7.09%. While not as high as VIRI, UNCY still presents a positive growth outlook. Investors may find UNCY appealing due to its moderate growth potential compared to the significant downside risks of CELZ and VRAX.
